Literature DB >> 25218025

Synthesis and in vitro/in vivo evaluation of novel mono- and trivalent technetium-99m labeled ghrelin peptide complexes as potential diagnostic radiopharmaceuticals.

Przemysław Koźmiński1, Ewa Gniazdowska2.   

Abstract

INTRODUCTION: Ghrelin is an endogenous hormone present in blood. It is released from the oxyntic cells (X/A-like cells) of the stomach and fundus and can exist in two forms: as an acylated and des-acylated ghrelin. Ghrelin is an endogenous ligand of the growth hormone receptor (growth hormone secretagogue receptor, GHS-R). Overexpression of GHS-R1a receptor was identified in cells of different types of tumors (e.g. pituitary adenoma, neuroendocrine tumors of the thyroid, lung, breast, gonads, prostate, stomach, colorectal, endocrine and non-endocrine pancreatic tumors). This fact suggests that gamma radionuclide labeled ghrelin peptide may be considered as a potential diagnostic radiopharmaceutical.
METHODS: Ghrelin peptide labeled with mono- and trivalent technetium-99m complexes, (99m)Tc-Lys-GHR, has been prepared on the n.c.a. scale. The physicochemical (stability, charge, shape, lipophilicity) and biological (receptor affinity, biodistribution) properties of the conjugates have been studied relevant to use the conjugates as receptor-based diagnostic radiopharmaceuticals.
RESULTS: The obtained conjugates [(99m)Tc(CO)3LN,O(CN-Lys-GHR)](+), (99m)Tc(CO)3LS,O(CN-Lys-GHR) and (99m)Tc(NS3)(CN-Lys-GHR) show different shape, charge, lipophilicity and two of them, (99m)Tc(CO)3LS,O(CN-Lys-GHR) and (99m)Tc(NS3)(CN-Lys-GHR), high stability in neutral aqueous solutions, even in the presence of excess concentration of histidine/cysteine competitive standard ligands or human serum. The in vitro binding affinity of (99m)Tc-Lys-GHR conjugates with respect to growth hormone secretagogue receptor (GHS-R1a) present on DU-145 cells was in the range of IC50 from 45 to 54 nM. The conjugate (99m)Tc(CO)3LS,O(CN-Lys-GHR) exhibited excretion route by the liver and kidney in comparable degree, while the more lipophilic conjugate (99m)Tc(NS3)(CN-Lys-GHR)-mainly by the liver.
CONCLUSIONS: Basing on the results concerning physicochemical and biochemical properties, the conjugates (99m)Tc(CO)3LS,O(CN-Lys-GHR) and (99m)Tc(NS3)(CN-Lys-GHR) might be considered to be promising models for diagnostic radiopharmaceutical.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biodistribution; Cell line; DU-145; Ghrelin; Radiolabeling; Technetium-99m

Mesh:

Substances:

Year:  2014        PMID: 25218025     DOI: 10.1016/j.nucmedbio.2014.08.012

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  5 in total

1.  Development of a [68Ga]-ghrelin analogue for PET imaging of the ghrelin receptor (GHS-R1a).

Authors:  C L Charron; M S McFarland; S Dhanvantari; L G Luyt
Journal:  Medchemcomm       Date:  2018-09-17       Impact factor: 3.597

2.  Development of Fluorinated Non-Peptidic Ghrelin Receptor Ligands for Potential Use in Molecular Imaging.

Authors:  Rareş-Petru Moldovan; Sylvia Els-Heindl; Dennis J Worm; Torsten Kniess; Michael Kluge; Annette G Beck-Sickinger; Winnie Deuther-Conrad; Ute Krügel; Peter Brust
Journal:  Int J Mol Sci       Date:  2017-04-05       Impact factor: 5.923

3.  Development and Characterization of an 18F-labeled Ghrelin Peptidomimetic for Imaging the Cardiac Growth Hormone Secretagogue Receptor.

Authors:  Ahmed Abbas; Lihai Yu; Tyler Lalonde; Derek Wu; Jonathan D Thiessen; Leonard G Luyt; Savita Dhanvantari
Journal:  Mol Imaging       Date:  2018 Jan-Dec       Impact factor: 4.488

4.  Differential expression of ghrelin and GHSR via the mTOR pathway during the dynamic carcinogenic process involving oral, potentially malignant disorders.

Authors:  Jianing Lou; Lin Liu; Weizhen Zhang; Zengtong Zhou; Yuan Fan
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

Review 5.  A Decade's Progress in the Development of Molecular Imaging Agents Targeting the Growth Hormone Secretagogue Receptor.

Authors:  Marina D Childs; Leonard G Luyt
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.